At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 610 enrolled
Drug / intervention
CHF 718 pMDI +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An 8-week, Multicenter, Randomized, Double-blind, Placebo and Active-controlled, Parallel Group, Dose-ranging Study to Evaluate the Efficacy and Safety of 3 Doses of CHF 718 pMDI (HFA Beclomethasone Dipropionate Via Pressured Metered Dose Inhaler) in Asthmatic Subjects.
In Brief
A Phase 2 clinical trial evaluating CHF 718 pMDI, Placebo pMDI, and 1 other intervention for Asthma. Completed, enrolled 610 participants across 134 sites.
Detailed Summary
The purpose of this study is to evaluate the dose-response of different doses of CHF 781 Pressurized Metered Dose Inhaler (pMDI) on lung function and other clinical outcomes, to identify the optimal dose(s) in terms of benefit/ risk ratio for further development in the target patient population.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 2017
Enrollment StartJul 2017
Primary CompletionNov 2018
Study CompletionDec 2018
TodayJul 2026
First PostedMar 21, 2017
Enrollment StartJul 28, 2017
Primary CompletionNov 28, 2018
Study CompletionDec 5, 2018
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 9.3 years ago
Interventions
CHF 718 pMDIdrug
Dose Response: Test one of three different doses of CHF 718 pMDI
Placebo pMDIdrug
Placebo Control
Beclomethasone Dipropionate (BDP)drug
Active Control